Navigation Links
Leading Pharmaceutical Marketing Research and Consulting Company Introduces 'Intelligent Efficiency' Program

BLUE BELL, Pa., Feb. 1, 2012 /PRNewswire/ -- Evolution Marketing Research, the next generation pharmaceutical marketing research and consulting company, announced that it has proactively restructured in order to better take advantage of the evolving global pharmaceutical marketplace in coming years. As a keystone of this restructuring, the company has instituted a new strategy called "Intelligent Efficiency." This strategy is intended to allow the company to compete effectively in this new market environment with a streamlined organizational structure.

"Over the past decade, the pharmaceutical marketing research industry has known nothing but solid, often dramatic, growth. The pharmaceutical industry, however, has changed and the new definition of success in these trying economic times is stability rather than growth, in large part due to shrinking pharma marketing research budgets," said company Principal James Cummings

Evolution's founding principals look forward to a more stable market environment in the year to come which will allow for the development of new relationships in the biopharma industry. "By every definition of the term, Evolution had a stable year and is poised for success in the future," explains Daniel Slawe, Chief Operating Officer. "The restructuring of the company under our new Intelligent Efficiency program will allow us to continue to provide best-in-class service to our clients."

An important part of this drive will be the development of new and innovative research methodologies and products. "Evolution is constantly in the process of creating new key products, several of which will be launching over the course of this year [2012]," said Principal Dr. James Heasley. "This is in keeping with our corporate mission of continuing to innovate and lead in an industry that is always seeking to enhance efficiencies." In 2011, the company introduced a range of innovative methodologies such as the well-received PreSIM(SM) qualitative conjoint method and its ActiveInsight™ custom omnibus study. 

Through the Intelligent Efficiency initiative, Evolution is committed to introduction of new and original methodologies geared toward aiding clients to make the most of their resources.

About Evolution Marketing Research, LLC:

Evolution Marketing Research is a medical marketing research firm that provides qualitative and quantitative research, consulting services, project management, advisory board monitoring and other marketing research services to pharmaceutical, biotech and medical device companies all over the world. Company Principals John Taenzler, Ph.D., Jim Cummings, and James Heasley, Ph.D., who are backed by a seasoned team of analysts and researchers, bring their collective experience to bear on pharmaceutical projects at all phases of the product lifecycle, including opportunity and licensing assessments, product crafting in support of phase III clinical trial design, and development of the commercial platform for developmental and in-line products. To learn more, call (866) 486-0873 or visit  


Inna Lobanova-Heasley

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Evolution Marketing Research, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. iBioSeminars and iBioMagazine: Free, Online Biology Seminars and Short Talks by Leading Scientists
2. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
3. BioSpace Spotlights Leading Life Science Community
4. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
5. CenTrak, a Leading Real-Time Location System Provider, Unveils New Branding
6. Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
7. CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
8. Californias Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation
9. OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
10. Clinical Integration Enables Leading Health Systems to Deliver Higher Quality, Cost-Effective Care
11. Leading Life Sciences Luminaries Connect at Innovation Ireland Reception
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for ... of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference ... ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... , ... November 24, 2015 , ... The Academy of ... Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person ... few years. Many AMA members have embraced this type of racing and several new ...
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Twist ... announced that Emily Leproust, Ph.D., Twist Bioscience chief ... Jaffray Healthcare Conference on December 1, 2015 at ... Hotel in New York City. --> ... . Twist Bioscience is on Twitter. ...
(Date:11/24/2015)... , Nov. 24, 2015 Capricor Therapeutics, ... focused on the discovery, development and commercialization of first-in-class ... Chief Executive Officer, is scheduled to present at the ... at 10:50 a.m. EST, at The Lotte New York ... . . --> ...
Breaking Biology Technology:
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
(Date:10/26/2015)... 2015  Delta ID Inc., a company focused on ... PC devices, announced its ActiveIRIS® technology powers the iris ... launched by NTT DOCOMO, INC in Japan ... smartphone to include iris recognition technology, after a very ... in May 2015, world,s first smartphone to have this ...
(Date:10/22/2015)...  Synaptics (NASDAQ: SYNA ), a leading developer of human ... September 30, 2015. --> --> ... 66 percent over the comparable quarter last year to $470.0 million. ... million, or $0.62 per diluted share. --> ... of fiscal 2016 grew 39 percent over the prior year period ...
Breaking Biology News(10 mins):